About Us

Focus-X Therapeutics, founded in 2020, is a preclinical stage biotechnology company committed to the discovery and development of cutting-edge radiopharmaceuticals.  We focus on unmet needs in cancer diagnosis and therapy by applying our theragnostic approach to solid tumors with very low five-year survival rate.  We bring our proprietary radioligand therapy (RLT) to precisely deliver alpha or beta emitters to breakdown cancer cell DNA.  As an emerging leader of RLT, our mission is to release the true potential of such modality by leveraging our world-class peptide drug discovery platform and joining force with top radiopharmaceutical partners.

Management Team

  • Fa LiuPhD

    Co-Founder, CEO

    Dr. Liu has over 15 years drug discovery and development experience in major pharmaceutical companies. Prior to founding Focus-X, he was the Head of Chemistry at Novo Nordisk Research Centers in the US leading the peptide and protein therapeutics discovery (2016-2020). Before joining Novo, he was the Head of Chemistry at Calibrium LLC where he played instrumental roles in building up the company pipeline that promoted its acquisition by Novo Nordisk (2014-2015). Dr. Liu started his industrial career at Eli Lilly where he led multiple peptide lead optimization efforts and established the well-recognized modern insulin chemistries (2009-2014). Prior to Lilly, Dr. Liu worked at National Cancer Institute focusing on cancer drug discovery (2004-2009). He received his Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2004. Dr. Liu has led the identification of significant number of clinical candidates, three of them have reached human studies. He also contributed to the discovery of LY3209590 (phase II) and the approved drug Lyumjev®. Dr. Liu has published more than 80 research articles and patent applications. 

  • Qi HuiMS

    Co-Founder, COO
    Mr. Hui has more than 20 years experience in pharmaceutical industries, started at ChemWerth (2002-2006), then Novartis (2006-2009) and most recently Eli Lilly (2009-2020). Prior to founding Focus-X, he has assumed multifunctional responsibilities at Novartis and Eli Lilly including New Product Development, Sourcing/Business Development and Procurement. Recently, he has also been serving as a Research Operation Consultant for biotech startups. Mr. Hui has extensive experiences in pharmaceutical sourcing, CRO & CMO management, research operations and project managements. In addition, he possesses rich knowledge of ICH guidelines, FDA cGMP and GLP regulations. Mr. Hui received his Master degree from Northwest University and Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2001.
  • Alla DarwishPhD, MBA

    Head of Radiochemistry

    Dr. Darwish started his career in Nuclear Medicine during his Postdoctoral Fellowship (2009-2011) with Prof. John Valliant lab at McMaster University where he invented TAAG®, an iodine carrier moiety, that facilitates better pharmacokinetic profiles of radiopharmaceuticals. Alla later joined the Centre for Probe Development and Commercialization (CPDC) as a scientist to lead their efforts in developing radiotherapeutics (2011-2017). He was the inventor of the Fast Clear™ platform that raised over $160 million in series A&B financing to establish the spin-off company Fusion Pharmaceuticals.  This startup went on to file on IPO in June of 2020 at NASDAQ (FUSN) with initial raise of $280 million. This platform generated a lead therapeutic candidate which is currently in phase I clinical trials. After that, Alla joined a University of Toronto Start-up, Dalriada Therapeutics, that focused on bringing covalent inhibitors to the clinic with oncology applications (2017-2019).  As the first employee at Dalriada Therapeutics, Alla played an instrumental role in scaling the start-up to 28 employees and led the R&D team to commercialize a promising class of therapeutics with a nomination of a clinical lead. Dr. Darwish received a Bachelor in Biochemistry and a Doctorate in Organic Chemistry from the University of Waterloo, followed by a Master of Business Administration from Lazaridis School of Business and Economics.




Dr. Liu has over 15 years drug discovery and development experience in major pharmaceutical companies. Prior to founding Focus-X, he was the Head of Chemistry at Novo Nordisk Research Centers in the US leading the peptide and protein therapeutics discovery (2016-2020). Before joining Novo, he was the Head of Chemistry at Calibrium LLC where he played instrumental roles in building up the company pipeline that promoted its acquisition by Novo Nordisk (2014-2015). Dr. Liu started his industrial career at Eli Lilly where he led multiple peptide lead optimization efforts and established the well-recognized modern insulin chemistries (2009-2014). Prior to Lilly, Dr. Liu worked at National Cancer Institute focusing on cancer drug discovery (2004-2009). He received his Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2004. Dr. Liu has led the identification of significant number of clinical candidates, three of them have reached human studies. He also contributed to the discovery of LY3209590 (phase II) and the approved drug Lyumjev®. Dr. Liu has published more than 80 research articles and patent applications. 

Mr. Hui has more than 20 years experience in pharmaceutical industries, started at ChemWerth (2002-2006), then Novartis (2006-2009) and most recently Eli Lilly (2009-2020). Prior to founding Focus-X, he has assumed multifunctional responsibilities at Novartis and Eli Lilly including New Product Development, Sourcing/Business Development and Procurement. Recently, he has also been serving as a Research Operation Consultant for biotech startups. Mr. Hui has extensive experiences in pharmaceutical sourcing, CRO & CMO management, research operations and project managements. In addition, he possesses rich knowledge of ICH guidelines, FDA cGMP and GLP regulations. Mr. Hui received his Master degree from Northwest University and Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2001.

Dr. Darwish started his career in Nuclear Medicine during his Postdoctoral Fellowship (2009-2011) with Prof. John Valliant lab at McMaster University where he invented TAAG®, an iodine carrier moiety, that facilitates better pharmacokinetic profiles of radiopharmaceuticals. Alla later joined the Centre for Probe Development and Commercialization (CPDC) as a scientist to lead their efforts in developing radiotherapeutics (2011-2017). He was the inventor of the Fast Clear™ platform that raised over $160 million in series A&B financing to establish the spin-off company Fusion Pharmaceuticals.  This startup went on to file on IPO in June of 2020 at NASDAQ (FUSN) with initial raise of $280 million. This platform generated a lead therapeutic candidate which is currently in phase I clinical trials. After that, Alla joined a University of Toronto Start-up, Dalriada Therapeutics, that focused on bringing covalent inhibitors to the clinic with oncology applications (2017-2019).  As the first employee at Dalriada Therapeutics, Alla played an instrumental role in scaling the start-up to 28 employees and led the R&D team to commercialize a promising class of therapeutics with a nomination of a clinical lead. Dr. Darwish received a Bachelor in Biochemistry and a Doctorate in Organic Chemistry from the University of Waterloo, followed by a Master of Business Administration from Lazaridis School of Business and Economics.




  • Mike Li MS

    Head of CMC
    Mr. Li has nearly 40 years‘ experience in pharmaceutical development involving small molecule, peptide and antibody drugs. He has supported IND-enabling studies and regulatory submissions in multiple regions including US, Europe, China and Australia, and been responsible for the CMC section of 2 NDAs, more than 30 INDs and 70 ANDAs (abbreviated new drug application). Mr. Li has served as key leadership roles in several companies including Threshold Pharmaceuticals (Sr. Director of Product Development), Matrix Pharmaceuticals (Director of Advanced Product & Process Development), Quad Pharmaceuticals and Bausch & Lomb. Mr. Li received his Master degree in chemical engineering from University of Illinois at Chicago (M.S.)
Mr. Li has nearly 40 years‘ experience in pharmaceutical development involving small molecule, peptide and antibody drugs. He has supported IND-enabling studies and regulatory submissions in multiple regions including US, Europe, China and Australia, and been responsible for the CMC section of 2 NDAs, more than 30 INDs and 70 ANDAs (abbreviated new drug application). Mr. Li has served as key leadership roles in several companies including Threshold Pharmaceuticals (Sr. Director of Product Development), Matrix Pharmaceuticals (Director of Advanced Product & Process Development), Quad Pharmaceuticals and Bausch & Lomb. Mr. Li received his Master degree in chemical engineering from University of Illinois at Chicago (M.S.)

Board of Directors

  • Fa LiuPhD

    Board Member
    Dr. Liu has over 15 years drug discovery and development experience in major pharmaceutical companies. Prior to founding Focus-X, he was the Head of Chemistry at Novo Nordisk Research Centers in the US leading the peptide and protein therapeutics discovery (2016-2020). Before joining Novo, he was the Head of Chemistry at Calibrium LLC where he played instrumental roles in building up the company pipeline that promoted its acquisition by Novo Nordisk (2014-2015). Dr. Liu started his industrial career at Eli Lilly where he led multiple peptide lead optimization efforts and established the well-recognized modern insulin chemistries (2009-2014). Prior to Lilly, Dr. Liu worked at National Cancer Institute focusing on cancer drug discovery (2004-2009). He received his Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2004. Dr. Liu has led the identification of significant number of clinical candidates, three of them have reached human studies. He also contributed to the discovery of LY3209590 (phase II) and the approved drug Lyumjev®. Dr. Liu has published more than 80 research articles and patent applications. 
  • Qi HuiMS

    Board Member
    Mr. Hui has more than 20 years experience in pharmaceutical industries, started at ChemWerth (2002-2006), then Novartis (2006-2009) and most recently Eli Lilly (2009-2020). Prior to founding Focus-X, he has assumed multifunctional responsibilities at Novartis and Eli Lilly including New Product Development, Sourcing/Business Development and Procurement. Recently, he has also been serving as a Research Operation Consultant for biotech startups. Mr. Hui has extensive experiences in pharmaceutical sourcing, CRO & CMO management, research operations and project managements. In addition, he possesses rich knowledge of ICH guidelines and FDA cGMP and GLP regulations. Mr. Hui received his Master degree from Northwest University and Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2001.
  • Yiwei ZongPhD

    Board Member
    Dr. Zong is the Co-Founder and Chief Operating Officer of Anji Pharma, a clinical-stage biopharmaceutical company. He also serves as a director on the boards of multiple biotech companies. Dr. Zong is an experienced investor and successful entrepreneur bringing valuable business strategy insights to Focus-X. Prior to founding Anji, he was a Partner at biotech VC funds, where he led a number of high-return investments.  Dr. Zong received his Ph.D. in Biomedicine from the University of Pennsylvania and is a Chartered Financial Analyst. 
Dr. Liu has over 15 years drug discovery and development experience in major pharmaceutical companies. Prior to founding Focus-X, he was the Head of Chemistry at Novo Nordisk Research Centers in the US leading the peptide and protein therapeutics discovery (2016-2020). Before joining Novo, he was the Head of Chemistry at Calibrium LLC where he played instrumental roles in building up the company pipeline that promoted its acquisition by Novo Nordisk (2014-2015). Dr. Liu started his industrial career at Eli Lilly where he led multiple peptide lead optimization efforts and established the well-recognized modern insulin chemistries (2009-2014). Prior to Lilly, Dr. Liu worked at National Cancer Institute focusing on cancer drug discovery (2004-2009). He received his Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2004. Dr. Liu has led the identification of significant number of clinical candidates, three of them have reached human studies. He also contributed to the discovery of LY3209590 (phase II) and the approved drug Lyumjev®. Dr. Liu has published more than 80 research articles and patent applications. 
Mr. Hui has more than 20 years experience in pharmaceutical industries, started at ChemWerth (2002-2006), then Novartis (2006-2009) and most recently Eli Lilly (2009-2020). Prior to founding Focus-X, he has assumed multifunctional responsibilities at Novartis and Eli Lilly including New Product Development, Sourcing/Business Development and Procurement. Recently, he has also been serving as a Research Operation Consultant for biotech startups. Mr. Hui has extensive experiences in pharmaceutical sourcing, CRO & CMO management, research operations and project managements. In addition, he possesses rich knowledge of ICH guidelines and FDA cGMP and GLP regulations. Mr. Hui received his Master degree from Northwest University and Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2001.
Dr. Zong is the Co-Founder and Chief Operating Officer of Anji Pharma, a clinical-stage biopharmaceutical company. He also serves as a director on the boards of multiple biotech companies. Dr. Zong is an experienced investor and successful entrepreneur bringing valuable business strategy insights to Focus-X. Prior to founding Anji, he was a Partner at biotech VC funds, where he led a number of high-return investments.  Dr. Zong received his Ph.D. in Biomedicine from the University of Pennsylvania and is a Chartered Financial Analyst. 

Strategic Advisor

  • Dennis BrownPhD

    Dr. Brown has served as the Chairman of Mountain View Pharmaceuticals’s Board of Directors since 2000 and has more than twenty years of drug discovery and development experience.  He is the Founder and President of Valent Technologies, LLC and Co-founder and Chief Scientific Officer and a Director of DelMar Pharmaceuticals.  In 1999, he founded ChemGenex Therapeutics, which merged with a publicly traded Australian company in 2004 to become ChemGenex Pharmaceuticals, of which he served as President and a Director until 2009.  He was previously a Co-founder of Matrix Pharmaceutical, Inc., where he served as Vice President (VP) of Scientific Affairs from 1985-1995 and as VP, Discovery Research, from 1995-1999.  He also previously served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology at Stanford University Medical School. He received his B.A. in Biology and Chemistry, M.S. in Cell Biology and Ph.D. in Radiation and Cancer Biology, all from New York University.  Dr. Brown is an inventor on about 34 issued US patents and applications, many with foreign counterparts.
Dr. Brown has served as the Chairman of Mountain View Pharmaceuticals’s Board of Directors since 2000 and has more than twenty years of drug discovery and development experience.  He is the Founder and President of Valent Technologies, LLC and Co-founder and Chief Scientific Officer and a Director of DelMar Pharmaceuticals.  In 1999, he founded ChemGenex Therapeutics, which merged with a publicly traded Australian company in 2004 to become ChemGenex Pharmaceuticals, of which he served as President and a Director until 2009.  He was previously a Co-founder of Matrix Pharmaceutical, Inc., where he served as Vice President (VP) of Scientific Affairs from 1985-1995 and as VP, Discovery Research, from 1995-1999.  He also previously served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology at Stanford University Medical School. He received his B.A. in Biology and Chemistry, M.S. in Cell Biology and Ph.D. in Radiation and Cancer Biology, all from New York University.  Dr. Brown is an inventor on about 34 issued US patents and applications, many with foreign counterparts.

Scientific Advisor

  • Andrew WangMD

    Dr. Wang is a physician scientist and full Professor in the Department of Radiation Oncology at the University of North Carolina (UNC) School of Medicine. He is a member of the The American Institute for Medical and Biological Engineering (AIMBE) and the The American Society for Clinical Investigation (ASCI). He is the Director of Clinical and Translational Research in his department. He is also the co-Director of the T32 Carolina Cancer Nanomedicine Training Program. Dr. Wang also holds adjunct positions in the Department of Urology and Department of Biomedical Engineering. Dr. Wang obtained his MD from the Harvard-MIT Health Sciences Technology program at Harvard Medical School. He then completed clinical oncology training in the Harvard Radiation Oncology Program. During residency, Dr. Wang completed a postdoctoral Fellowship under the dual mentorship of Prof. Robert Langer at MIT and Dr. Farokhzad at BWH. Dr. Wang’s research is focused on the application of biomedical engineering to improve cancer treatment. He has a special interest in therapeutic isotopes and he is a member of the committee for Better Integrating Radionuclide Therapy into the structure of the AAPM (American Association of Physicists in Medicine).

  • Carolyn AndersonPhD

    Dr. Anderson is the Simón-Ellebracht Professor of Medicinal Chemistry and Professor of Radiology at the University of Missouri. Her research interests include the development and evaluation of novel radiometal-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of cancer and other diseases. She has co-authored over 190 publications, mostly in the area of developing radiopharmaceuticals for oncological imaging and therapy. A current focus of her research lab is the development of imaging agents for up-regulated receptors on immune cells that are involved in inflammation related primary tumor growth and cancer metastasis, and sickle cell disease. Dr. Anderson has received numerous honors, including the Michael J. Welch Award from the SNMMI in 2012, a Distinguished Investigator Award from the Academy of Radiology Research in 2014, Fellow of the SNMMI and fellow of the World Molecular Imaging Society in 2019, and the Paul C. Aebersold Award of the SNMMI in 2020. 

  • Steve ChoMD, PhD

    Dr. Cho is an Associate Professor in the Nuclear Medicine and Molecular Imaging Section of the Department of Radiology, University of Wisconsin-Madison. He is engaged in translational research as Director of the Translational Imaging Research Core at the UW Carbone Comprehensive Cancer Center, Director of the new cGMP Radiopharmaceutical Production Facility, and Associate Director of the UW PET Center. Dr. Cho graduated from the New York University School of Medicine and received medical training from the Johns Hopkins Hospital. He stayed on at Johns Hopkins as an Assistant Professor of Radiology and Oncology before moving to UW–Madison in 2014. Dr. Cho was the recipient of the 2008 RSNA Research Scholar Award, 2008 Prostate Cancer Foundation (PCF) Young Investigator Award, 2011 PCF Creativity Award, and 2013 Society of Nuclear Medicine Editor’s Choice Award. He has served on the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Center for Molecular Imaging Innovation and Translation (CMIIT) Board of Directors and will serve in the SNMMI Therapy Center of Excellence (Therapy COE) as Therapy Center Scientific Program Committee Vice Chair.

Dr. Wang is a physician scientist and full Professor in the Department of Radiation Oncology at the University of North Carolina (UNC) School of Medicine. He is a member of the The American Institute for Medical and Biological Engineering (AIMBE) and the The American Society for Clinical Investigation (ASCI). He is the Director of Clinical and Translational Research in his department. He is also the co-Director of the T32 Carolina Cancer Nanomedicine Training Program. Dr. Wang also holds adjunct positions in the Department of Urology and Department of Biomedical Engineering. Dr. Wang obtained his MD from the Harvard-MIT Health Sciences Technology program at Harvard Medical School. He then completed clinical oncology training in the Harvard Radiation Oncology Program. During residency, Dr. Wang completed a postdoctoral Fellowship under the dual mentorship of Prof. Robert Langer at MIT and Dr. Farokhzad at BWH. Dr. Wang’s research is focused on the application of biomedical engineering to improve cancer treatment. He has a special interest in therapeutic isotopes and he is a member of the committee for Better Integrating Radionuclide Therapy into the structure of the AAPM (American Association of Physicists in Medicine).

Dr. Anderson is the Simón-Ellebracht Professor of Medicinal Chemistry and Professor of Radiology at the University of Missouri. Her research interests include the development and evaluation of novel radiometal-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of cancer and other diseases. She has co-authored over 190 publications, mostly in the area of developing radiopharmaceuticals for oncological imaging and therapy. A current focus of her research lab is the development of imaging agents for up-regulated receptors on immune cells that are involved in inflammation related primary tumor growth and cancer metastasis, and sickle cell disease. Dr. Anderson has received numerous honors, including the Michael J. Welch Award from the SNMMI in 2012, a Distinguished Investigator Award from the Academy of Radiology Research in 2014, Fellow of the SNMMI and fellow of the World Molecular Imaging Society in 2019, and the Paul C. Aebersold Award of the SNMMI in 2020. 

Dr. Cho is an Associate Professor in the Nuclear Medicine and Molecular Imaging Section of the Department of Radiology, University of Wisconsin-Madison. He is engaged in translational research as Director of the Translational Imaging Research Core at the UW Carbone Comprehensive Cancer Center, Director of the new cGMP Radiopharmaceutical Production Facility, and Associate Director of the UW PET Center. Dr. Cho graduated from the New York University School of Medicine and received medical training from the Johns Hopkins Hospital. He stayed on at Johns Hopkins as an Assistant Professor of Radiology and Oncology before moving to UW–Madison in 2014. Dr. Cho was the recipient of the 2008 RSNA Research Scholar Award, 2008 Prostate Cancer Foundation (PCF) Young Investigator Award, 2011 PCF Creativity Award, and 2013 Society of Nuclear Medicine Editor’s Choice Award. He has served on the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Center for Molecular Imaging Innovation and Translation (CMIIT) Board of Directors and will serve in the SNMMI Therapy Center of Excellence (Therapy COE) as Therapy Center Scientific Program Committee Vice Chair.

  • Weibo CaiPhD

    Dr. Cai is a Vilas Distinguished Achievement Professor of Radiology, Medical Physics, Biomedical Engineering, Materials Science & Engineering, and Pharmaceutical Sciences at the University of Wisconsin-Madison, USA. He received a BS degree in Chemistry from Nanjing University, China (1995) and a PhD degree in Chemistry from UC San Diego (2004). Dr. Cai’s research is primarily focused on molecular imaging and nanobiotechnology (http://mi.wisc.edu). Dr. Cai has authored >330 articles (total citation: >26,000; h-index: 83), and edited 3 books. He has received many awards, including European Association of Nuclear Medicine (EANM) Springer Prize (2011&2013), American Cancer Society Research Scholar (2013), Fellow of AIMBE (2018), Fellow of SNMMI (2019), among others. Dr. Cai has served on the Editorial Board of >20 scientific journals and participated in many grant review panels (e.g. NIH, DOD, NSF, CPRIT, etc.). He is currently Editor-in-Chief of American Journal of Nuclear Medicine and Molecular Imaging, as well as Journal of Nanobiotechnology (2019 Impact Factor: 6.518). What Dr. Cai is most proud of is that his trainees at UW-Madison have received >100 awards, such as 2012 SNMMI Berson-Yalow Award, multiple SNMMI Young Investigator Awards, among others. More than a dozen of them have started independent research groups at world-class universities. 




  • Xiang S. YePhD

    Dr. Ye is a seasoned cancer biologist veteran and a well-recognized leader in the field of cancer drug discovery and development. He recently joined Ionova Life Science as the CSO. Prior to Ionova,  Dr. Ye spent more than 20 years at Eli Lilly and played multiple critical management roles, most recently as the Head of Lilly Oncology Research China/Asia. At Lilly, he contributed to the discovery and development of  8 clinical candidates, including the approved abemaciclib (Verzenio®) and one currently at Phase II. Abemaciclib is the best-in-class CDK4/6 inhibitor, which received FDA breakthrough medicine designation and was approved in 2017 through priority review. Dr. Ye also initiated genomic and epigenomic-based cancer drug discovery research efforts at Lilly, and developed key translational research platforms and technological capabilities to support Lilly Oncology global R&D strategy. In addition, Dr. Ye has been playing several leadership roles in various industry consortium programs. 




  • Zibo LiPhD

    Dr. Li obtained his PhD in chemistry from the University of Virginia in 2006. After a postdoctoral position at the Stanford University from 2006-2008, he joined the Molecular Imaging and Biomarker Research division, Siemens Inc as a senior scientist. In Nov 2008, he was recruited as an Assistant Professor at the USC Radiology Department and served as the chief of radiochemistry research at USC molecular imaging center. In 2014, he moved to UNC Chapel Hill and he is currently a full professor in Radiology Department and Biomedical Research Imaging Center. Dr. Li is also the Director of Cyclotron and Radiochemistry Program at UNC Chapel Hill. Dr. Li’s research areas include the development of novel labeling methods, multimodality probes, and nanomaterials for visualization and quantification of various molecular targets related to cancer, diabetes, and cardiovascular disease. In addition to traditional 18F, 11C, and 64Cu labeling methods, Dr. Li also established the field of photoredox radiofluorination in collaboration with Dr. David Nicewicz from the chemistry department of UNC Chapel Hill.

Dr. Cai is a Vilas Distinguished Achievement Professor of Radiology, Medical Physics, Biomedical Engineering, Materials Science & Engineering, and Pharmaceutical Sciences at the University of Wisconsin-Madison, USA. He received a BS degree in Chemistry from Nanjing University, China (1995) and a PhD degree in Chemistry from UC San Diego (2004). Dr. Cai’s research is primarily focused on molecular imaging and nanobiotechnology (http://mi.wisc.edu). Dr. Cai has authored >330 articles (total citation: >26,000; h-index: 83), and edited 3 books. He has received many awards, including European Association of Nuclear Medicine (EANM) Springer Prize (2011&2013), American Cancer Society Research Scholar (2013), Fellow of AIMBE (2018), Fellow of SNMMI (2019), among others. Dr. Cai has served on the Editorial Board of >20 scientific journals and participated in many grant review panels (e.g. NIH, DOD, NSF, CPRIT, etc.). He is currently Editor-in-Chief of American Journal of Nuclear Medicine and Molecular Imaging, as well as Journal of Nanobiotechnology (2019 Impact Factor: 6.518). What Dr. Cai is most proud of is that his trainees at UW-Madison have received >100 awards, such as 2012 SNMMI Berson-Yalow Award, multiple SNMMI Young Investigator Awards, among others. More than a dozen of them have started independent research groups at world-class universities. 




Dr. Ye is a seasoned cancer biologist veteran and a well-recognized leader in the field of cancer drug discovery and development. He recently joined Ionova Life Science as the CSO. Prior to Ionova,  Dr. Ye spent more than 20 years at Eli Lilly and played multiple critical management roles, most recently as the Head of Lilly Oncology Research China/Asia. At Lilly, he contributed to the discovery and development of  8 clinical candidates, including the approved abemaciclib (Verzenio®) and one currently at Phase II. Abemaciclib is the best-in-class CDK4/6 inhibitor, which received FDA breakthrough medicine designation and was approved in 2017 through priority review. Dr. Ye also initiated genomic and epigenomic-based cancer drug discovery research efforts at Lilly, and developed key translational research platforms and technological capabilities to support Lilly Oncology global R&D strategy. In addition, Dr. Ye has been playing several leadership roles in various industry consortium programs. 




Dr. Li obtained his PhD in chemistry from the University of Virginia in 2006. After a postdoctoral position at the Stanford University from 2006-2008, he joined the Molecular Imaging and Biomarker Research division, Siemens Inc as a senior scientist. In Nov 2008, he was recruited as an Assistant Professor at the USC Radiology Department and served as the chief of radiochemistry research at USC molecular imaging center. In 2014, he moved to UNC Chapel Hill and he is currently a full professor in Radiology Department and Biomedical Research Imaging Center. Dr. Li is also the Director of Cyclotron and Radiochemistry Program at UNC Chapel Hill. Dr. Li’s research areas include the development of novel labeling methods, multimodality probes, and nanomaterials for visualization and quantification of various molecular targets related to cancer, diabetes, and cardiovascular disease. In addition to traditional 18F, 11C, and 64Cu labeling methods, Dr. Li also established the field of photoredox radiofluorination in collaboration with Dr. David Nicewicz from the chemistry department of UNC Chapel Hill.

Investors